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Stem cell research is attracting wide attention as a promising and fast-growing 
field in Latin America, as it is worldwide. Many countries in the region have defined 
Regenerative Medicine as a research priority and a focus of investment. This field 
generates not only opportunities but also regulatory, technical and operative 
challenges. In this review, scientists from Uruguay, Mexico, Chile, Brazil and Argentina 
provide their view on stem cell research in each of their countries. Despite country-
specific characteristics, all countries share several issues such as regulatory challenges. 
Key initiatives of each country to promote stem cell research are also discussed. As 
a conclusion, it is clear that regional integration should be more emphasized and 
international collaboration, promoted.
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Background
Latin America is a fast-growing region con-
scious of the relevance of stem cell research 
for the development of Regenerative Medi-
cine, which we think will play a major role in 
healthcare. In October 2014, the authors of 
this review met at the I Latin American, VIII 
Brazilian and I Argentine Congress of Stem 
Cells and Cell Therapy that took place in Foz 
de Iguazú, Brazil. We decided to write about 
stem cell research in these countries since 
we detected common setbacks and areas of 
opportunity (Table 1). We hope that the pre-
sented view is useful to join efforts in Latin 
America countries and tackle problems such 
as regulatory issues and also set up regional 
collaborations in complementary areas. In 
addition, international collaboration to foster 
human capability building and technological 
transfer in key research areas is critical for the 
field to develop.
Stem cell research in Uruguay
General vision
Uruguay is the second smallest nation in size 
in South America with 3.3 million people. 
According to the World Bank, Uruguay 
spends about 0.4% of its gross domestic 
product (GDP) on research and develop-
ment (R&D; Table 2) [2,3]. According to cal-
culations of the Organization for Economic 
Cooperation and Development, this rate 
should double in the next 5 years to 1.5% 
by 2030.
As is typical throughout the region, the 
public sector is responsible for most of the 
country’s R&D spending. This is the case 
of the Ministerial Bureau for Innovation, in 
which four ministries interact together with 
the Office of Budget and Planning in order 
to define general policies; the Sectorial Com-
mission for Scientific Research (CSIC) at the 
public ‘Republic University’ (UR); the Direc-
torate of Innovation, Science and Technology 
for Development of the Ministry of Educa-
tion and the National Agency for Research 
and Innovation (ANII) [4].
CSIC is an organization that promotes 
research at the university through several 
programs for the allocation of competi-
tive grants. In 1985, when democracy was 
restored, Uruguay had to start the process of 
rebuilding its ability to undertake research 
in the fields of science and medicine. Crucial 
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to this effort was the creation of several programs for 
research promotion like the Program for the Devel-
opment of Basic Sciences (PEDECIBA), the Program 
for Technological Development and the Program for 
Biomedical Research (PROINBIO). PEDECIBA was 
key to the reorganization of research in biology and 
other basic sciences. While biological research expo-
nentially grew between 1985 and 1998, the generation 
of medical research during this period was poor. In an 
effort to address this problem, the PROINBIO was set 
up in the School of Medicine from the UR (SM-UR) 
to foster medical research by introducing master and 
doctorate degrees in biomedicine [5]. Although other 
schools of the UR perform health-related research, 
the SM-UR is the main producer of health research in 
the country [6]. In 2006, ANII was created as a public 
nonstate body to promote scientific and technological 
development and innovation. In 2007, the National 
System of Researchers was established to encourage 
research dedication through a system of economic 
incentives [7,8]. The National Institute for Donation 
and Transplantation (INDT) is the only governmen-
tal organization responsible for the regulation, policy 
and management of donation and transplantation 
of cells, tissues and organs operating within the UR 
and the Ministry of Health (MH) [9,10]. In Uruguay, 
there is extensive experience in hematopoietic stem 
cell transplantation, which is funded by the National 
Resources Fund allowing data centralization and 
research in this field [11,12].
Stem cell regulation in Uruguay
The MH is responsible for approving programs and 
authorizing centers to work with human stem cells 
with either clinical or nonclinical purposes. Each pro-
gram and center with their human resources is tech-
nically and ethically evaluated before being enabled 
to develop human stem cell research. An unsolved 
problem in Uruguay is the existence of clinics offer-
ing unproven stem cells treatments. These clinics 
have established before approved laws and continue 
to be operative. In the last years, the National Eth-
ics Committee for Human Research and the Ethics 
Committee of the Medical College from Uruguay 
were created and began to work in the regulatory 
field.
In the last years and due to private clinics offer-
ing stem cells banking and therapies, the Uruguayan 
authorities were concerned about the security and 
safety of these procedures. Thus, a strategic plan was 
developed by promoting regulation about standards, 
quality control and safety for cells and human tissue 
transplantation [13], as well as for research involving 
human beings [14].C
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Stem cell initiatives in Uruguay
The population of Uruguay is old with high incidence 
of degenerative and cardiovascular diseases simi-
larly to developed countries. This population profile 
reflects a need to develop, or adopt once approved, 
similar therapies as the ones underdevelopment in 
developed countries. In 2009, the project ‘Creation 
and Development of Cell Therapy and Regenerative 
Medicine (CTRM) Area at the Clinical Hospital’ 
was approved for funding by CSIC-UR. The proj-
ect objectives are to: consolidate a multidisciplinary 
academic group, develop a CTRM Program, create 
a Cell Therapy Unit, develop research projects and 
provide human resources training in this field. In 
2013, this initiative was declared of national inter-
est by the MH and in 2014, a strategic alliance was 
established with the INDT for the construction of a 
GMP Facility for Advanced Therapies including the 
Tissue Engineering Laboratory and the Cell Ther-
apy Unit, transforming the proposal in a national 
project with academic, scientific and healthcare rel-
evance. In addition, the MH decided the creation 
of the National Public Umbilical Cord Blood Bank, 
which was inaugurated in 2014 in the Clinical Hos-
pital Dr Manuel Quintela from the UR under the 
direction of INDT [13].
Other research institutions related with stem cell 
research and tissue engineering in Uruguay are the 
Biological Research Institute ‘Clemente Estable,’ the 
Pasteur Institute of Montevideo, the Uruguayan Cen-
ter of Molecular Imaging and the Pando Technologi-
cal Pole (School of Chemistry Faculty and Industry). 
Besides, there is a research group in the UR working on 
stem cell therapies in Veterinary Medicine.
Some examples of stem cell research initiatives 
include, but are not restricted to, studies on mesen-
chymal stromal cells (MSCs) properties from differ-
ent sources, growth on scaffolds, effects on Parkin-
son’s disease and ischemic myocardial disease animal 
models, adult neurogenesis, clinical studies on bone 
marrow derived stem cells transplantation in patients 
with venous chronic ulcers and open fractures of lower 
limbs. No research with embryonic stem cells is being 
performed.
Strengths, weaknesses & opportunities in 
Uruguay
Despite the increase in national investment in science 
in the last years, funding remains insufficient to meet 
research needs and scientists’ salaries are still low. This 
is particularly evident in health research and therefore 
affects research on stem cells and regenerative medi-
cine. Average amounts available per project are small 
in comparison with the international context and the 
number of research teams that usually have access to 
international research funds is limited. There is also 
little, if any, research conducted by multinational pri-
vate companies in Uruguay and the lack of research 
investment by the national private institutions prob-
ably contributes. In this context, the UR has played a 
key role in keeping health research alive, while fund-
ing agencies depending on the national state have had 
a limited participation. This seems to correspond to a 
perception of health research as ‘nonstrategic,’ which 
in turn correlates with the absence of the MH from the 
newly created Ministerial Bureau for Innovation [6]. 
By contrast, the UR and the MH have prioritized the 
development of CTRM for its importance in human 
resources formation and to generate a critical mass of 
professionals in this field.
Besides, due to the scarce population is very dif-
ficult to make relevant clinical trials in this field in 
Uruguay, making crucial to perform multicentric and 
cooperative trials with other countries of the region. 
However, this characteristic allows centralizing and 
better regulating the activities in this field. The cre-
ation of a national GMP facility at the University Hos-
pital with mixed support will be very important for the 
development of this new discipline in Uruguay.
More randomized, controlled, multicentric clinical 
trials are needed and demographics of Uruguay make 
essential the collaboration with the region. Stem cell 
research is needed to have critical mass of researchers to 
avoid stem cell tourism and for intellectual sovereignty. 
These will provide appropriate facilities and trained 
staff for stem cells research and also improve collabo-
ration with developed countries to translate validated 
therapies to South American countries.
Stem cell research in Mexico
General vision
Mexico’s current population is over 122 million 
(Table 2). Mexico is part of the North America Free 
Trade Agreement together with Canada and the 
USA, belongs to the Organization for Economic Co-
operation and Development, is the 15th economy in 
the World and has an upper middle income [15]. The 
percentage of the GDP devoted to science and tech-
nology has been between 0.32 and 0.42% for the 
2003–2012 years, according to the National Council 
of Science and Technology (Table 2) [16]. Most research 
in the country is performed at public universities and 
research centers. The National Investigator System was 
created on 1984 and has been an important institu-
tional program, based on peer evaluation, to support 
the career of researchers. Currently, there are over 
23,000 investigators, resulting in 18.8 investigators 
per 100,000 inhabitants. Although there are not many 
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groups in Mexico working with stem/progenitor cells, 
last year the Mexican Society for Stem Cell Research 
was formed [17]. This group published in 2011 the 
book ‘Stem Cells and Regenerative Medicine,’ writ-
ten in Spanish, which can be useful from bachelor to 
graduate students. In addition, its members have orga-
nized scientific meetings with recognized professors in 
Mexico City in 2011 and 2013.
Stem cell initiatives in Mexico
The National Council of Science and Technology 
has several grant programs. A special subprogram in 
health-related projects aims to support transplanta-
tion and preservation of organs, tissues and stem cells. 
Unfortunately, only a handful of grants are given every 
year in this and other programs. As in many other 
countries, private banking of cord blood cells is offered 
to parents-to be. The loose information provided about 
the current usefulness of having these frozen cells has 
invigorated the conception that cell therapy might 
be useful in any needed way in the future. Costs for 
collecting and keeping the cells frozen can be sig-
nificant (US$1200–1800 for collection/processing 
+ US$130–175 per year for storage), creating a use 
restricted to those that can afford the price. However, 
public banks have been set up in large hospitals. The 
informed donation of cord blood to public banks does 
not involve payment, and the family is aware that they 
might or might not benefit from this public initiative.
Mexican early works on the biology of hemato-
poietic stem cells from cord blood [18,19], growth fac-
tor dependence of developing midbrain neural stem 
cells [20,21] and the effects of retinoic acid on embryonic 
stem cells [22] were made in the 1990s. Later on, papers 
describing mesenchymal cells from bone marrow from 
myelodysplastic patients [23], the isolation of stem 
cells from the enteric nervous system [24] and collab-
orative studies addressing factors that influence adult 
neural stem cell differentiation or survival [25,26] were 
reported. More recently, cancer-initiating cells from 
cervical lines were characterized [27]. Some published 
studies use mouse embryonic stem cells for neuronal 
differentiation [28–30] and there is no paper with a Mexi-
can corresponding author that uses human pluripotent 
cells. Thus, these examples show that hematopoietic, 
neural, embryonic, mesenchymal and cancer stem cells 
are the main interest of basic researchers in the country.
In the clinical setting, transplantation of hema-
topoietic cells is performed on regular basis to treat 
blood-related disorders after 1995 in both public and 
private institutions [31]. The most common procedure 
is donation of bone marrow or mobilized peripheral 
blood from a compatible donor. Recently, a public 
cord blood bank has provided hematopoietic cells for 
transplantation [32]. Public cord blood banks aimed 
for unrelated grafting might be of particular interest 
to developing countries [33], because the probability 
of finding a match is higher than with other donor 
cells [32]. Such public endeavors contrast and rise ethi-
cal concerns on the existence of private banks, because 
it is more altruistic to donate than to preserve the new-
born own cells [34]. In order to decrease costs associ-
ated to mobilized peripheral blood allotransplantation, 
a nonmyeloablative immunosuppressive scheme was 
designed to avoid the hospitalization required after 
myeloablation [35], with 81% of fully outpatient treat-
ment, significantly reducing the overall price of the 
procedure, which is desirable everywhere, but more 
important where resources are limited.
Stem cell regulation & strengths, weaknesses  
& opportunities in Mexico
The General Health Law [36] for the use of human 
organs, tissues, cells and corpses set the general frame, 
which unfortunately is related only to hematopoietic 
stem/progenitor cells, for both the procurement and 
Table 2. Economic support and stem cell research indicators for the presented countries. 
Country National GDP 
(US$ billions)
Population 
(millions of 
people)
Population of 
scientists
Overall science 
funding  
(% of GDP)
Stem cell 
publications (% 
of total country 
publications)
Funding of stem cell 
research  
(% of GDP)
Uruguay 55.7 3.4 538 0.43 1 Estimated <0.01%
Mexico 1261 122.3 23,000 0.42 0.2 Estimated <0.01%
Chile 277.2 17.6 6160 0.44 0.51 Estimated <0.01%
Brazil 2246 200.4 130,000 1.21 0.6 0.0021
Argentina 609.9 40.1 35,000† 0.65‡ 0.35§ Estimated <0.01%
Data from 2010 to 2013.
†Full-time scientists.
‡US$132.75 per inhabitant invested in research and development.
§Bone marrow transplantation studies not included. 
GDP: Gross domestic product.
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clinical applications. Then, there are specific guidelines 
in NOM-253-SSA1-2012 for the use of human blood 
and its components for therapeutic purposes. This reg-
ulatory frame can accommodate human cells that are 
obtained from neonatal o adult persons, leaving out the 
derivation of human embryonic stem cells. The rules for 
clinical application of human pluripotent cells are non-
existing. Cofepris (acronym for Federal Commission 
for the Protection against Sanitary Risks) grants Sani-
tary Certifications for medical facilities and holds the 
National Registry of Clinical Trials in Public and Pri-
vate Institutions. In addition to review cell-based appli-
cations, Cofepris has a large catalogue of health-related 
issues to oversee: quality of water, foods, drugs, medi-
cal equipment, cosmetic products; it also informs about 
potential risks in the environment or the workplace, and 
promotes prevention and good practices. This ample 
range of activities makes hard to keep up when sur-
veillance of medical practice is required. Cofepris can 
halt unproven clinical procedures, but this requires a 
complaint filed for the specific medical facility.
Recent changes introduced on 24 January 2013 to 
the General Health Law have opened a practice that 
was forbidden: to charge a recovery fee for procedures 
that involves therapies with cells, when they were 
altruistic and without cost to patients before. There 
is no justification for charging the patients receiving a 
not-proven therapy. The scientific basis and oversight 
approval are important to build confidence on hospi-
tals interested more in the patients than in their profit. 
It is the privilege, and also the duty of both patients 
and physicians to adhere to international standards 
and to report the results. The International Society for 
Stem Cell Research published guidelines a few years 
ago [37]. It is of the uttermost importance to cluster and 
coordinate hospitals to perform clinical trials involv-
ing stem/progenitor cells, since individual cases can 
be anecdotal, but double-blind procedures can signifi-
cantly contribute to agree on effectiveness, times for 
intervention, preparation/manipulation of cells and 
end points to be measured.
An area of opportunity to increase the investment 
is science and technology to 1% of the GDP and also 
to create at-large stem cell initiatives funded by the 
government. In particular, the creation of human plu-
ripotent stem cell banks and GMP facilities to prepare 
cells aimed for transplantation. This can be especially 
important in Latin America, where only a few human 
pluripotent lines have been derived, and the array of 
histocompatibility antigens (haplotypes) might pre-
clude the use of cell lines produced in developed coun-
tries. Training and enough funding shall promote a 
critical mass of people interested in stem cell projects 
that will benefit Mexico in the future.
Cancer is prevalent in Mexico as it is worldwide. 
However, the incidence of infant acute leukemias is 
particularly high [38]. Another important health prob-
lem in the Mexican population is obesity, often linked 
to metabolic syndrome. Removal of fat can be a source 
of mesenchymal cells that can be used for research 
purposes and, if applicable, also build a bank of donor 
cells for therapy. These challenging conditions offer a 
large number of patients that will encourage stem cell 
scientist to find novel treatments.
The public health system in Mexico is composed 
by federal and local institutions, but is saturated. This 
situation has favored private practice, because even 
when people are publicly insured, they do not want to 
wait. In addition, some private hospitals offer treat-
ments and equipment that are hard to find in public 
hospitals. The average income per person in Mexico 
is significantly less to that in the USA, which has pro-
moted that persons from this country cross the border 
to receive private consultation from dentists and med-
ical doctors, since the costs in Mexico are more afford-
able than in their home country. Stem cell treatments 
are also offered in Mexico to foreigners, most of the 
times patients that seek for a self-paid experimental 
treatment for intractable conditions, which can be 
ethically unfair, considering their serious illness [39].
Clearly, regulatory laws are lacking for human fer-
tilization, the derivation of human pluripotent stem 
cells, either form developing embryos [40] of from repro-
gramming somatic cells with the Yamanaka factors [41] 
and the clinical application of human pluripotent cells. 
Such laws are urgent and should consider the profes-
sional opinion of legislators, bioethicists and scientists. 
At-large institutions, such as the Mexican Academy of 
Sciences, the National Academy of Medicine and Cona-
cyt, ought to participate. The Human Fertilisation 
and Embryology Act of the UK is well-balanced and a 
good starting point for the discussion. Although Mex-
ico is permissive with regards to the use of adult stem 
cells, there are bioethical and political factors that will 
influence, and probably delay, this new legislation [42].
Stem cell research in Chile
General vision
Chile, like many Latin American countries, has not 
been oblivious from political turmoil until the late 
1980s. Since the early 1990s, with the advent of the 
democracy, Chile has developed interesting initiatives 
encouraging the development of Science and Technol-
ogy. More recently, in 2005 the National Innovation 
Council for Competitiveness was created, which aims 
to achieve an economic growth that allows the coun-
try to shorten, in minimum time, the economical gap 
that separates our country to developed countries. 
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Paradoxically, despite the diversity of instruments to 
promote the scientific-technological development the 
existing institution is extremely fragile and dispersed. 
Administration of science and research is scattered 
across government ministries. Among these are, 
by the volume of managed resources, Innova Chile 
CORFO and Chile’s National Commission for Scien-
tific and Technological Research (CONICYT). The 
first, which operates under the Ministry of Economy, 
has its focus on innovation and technology transfer. 
Chile’s main funding body, CONICYT, follows two 
broad strategic objectives: promoting the training of 
human capital and strengthening Chile’s scientific 
and technological base. Although the establishment 
of a Ministry of Science and Technology has long 
been under debate and the majority of the involved 
players agree that this is a necessary action to central-
ize a state policy, it was only this year that the actual 
government announced its creation.
The amount of Chilean Science and Technology 
has doubled in the last 10 years maintaining and even 
improving their quality when compared with many 
developed countries, being among the best in Latin 
America. In 2012, Chile was 46th in the Global 
Ranking of Journals and Country Scientific Indica-
tors, well below the USA but fourth in Latin Amer-
ica, after Brazil, Mexico and Argentina. However, 
since the year 2000 Chile has increased its scientific 
output, with an annual growth of 11% between 2006 
and 2011, with 75% of publications in English [43].
Chile leads the region in the number of patents 
granted, according to Nature suggesting greater 
investment from the country’s private sector [44]. 
Yet, barriers to the growth of its research commu-
nity remain. The total number of scientists, less than 
6200 in the country, is still very small; scientists 
comprise less than 0.1% of the Chilean workforce. 
These numbers are explained by the fact that Chile 
only invests approximately 0.45% of GDP in Science, 
Technology and Innovation, which internationally is 
very low. One of the central elements, as pointed in 
a recent study conducted by the Chilean Academy 
Science, is the dramatic lack of specialized human 
capital.
In relation to the training of researchers, efforts are 
being made. Since 2008, there have been 5809 gradu-
ate scholarships abroad, with expectations of increas-
ing this indicator in the near future [45]. Neverthe-
less, a big handicap is the repatriation; talented Latin 
American scientific investigators are not encouraged 
to return to their home regions after training con-
sidering that fewer than 200 awards were granted 
to incorporate scientists into the academic and 
industrial sectors.
Stem cell regulation in Chile
In Chile, there is no specific regulation regarding bio-
medical scientific research or clinical trials with human 
stem cells. Research is not specifically prohibited, but 
therapeutic and reproductive cloning and the funding 
of such activities are as of 1993. Furthermore, currently 
in Chile, there is no specific regulation regarding dona-
tion, testing, processing, preservation, storage, distri-
bution, application or treatment using human stem 
cells. In 2006, Chile’s government enacted a law that 
‘has as its purpose the protection of human life from 
the moment of conception, its physical and psychic 
integrity, as well as its diversity and genetic identity 
with regard to biomedical research and its clinical 
applications’.
Regulatory frameworks for cellular therapies are 
only now being established, driven greatly by the Aca-
demia; scientists, clinical researches and doctors are 
presently working in the establishment of The Chilean 
Society for Stem Cell Research and Regenerative Med-
icine. The legislation associated with the development 
and approval of market entry of products based on cells 
or tissues or use as medical devices, is another impor-
tant issue. A law that is built by legislators, bioethicists 
and scientists is mandatory in the short term.
Several private (family) banks are operating in San-
tiago; special concern in the area of ethical and scien-
tific implications of storing cord blood and advertis-
ing and the information given to parents about their 
potential benefits is required. Furthermore, the emer-
gence of the stem cell clinics for cosmetic purposes 
has raised concerns among scientists and doctors who 
raise serious scientific and ethical issues underlying this 
situation about the prestige of stem cell research and 
patient safety.
Stem cell initiatives & strengths, weaknesses  
& opportunities in Chile
Research in Chile is mainly performed at the academia 
(two-thirds of the academic publications come from 
just five universities). Chilean groups are well grounded 
in classic developmental biology. They produce inno-
vative and high-quality research and are striving hard 
to incorporate new technologies. There is currently a 
critical mass of young scientists working in this field. 
Several groups nowadays are working on stem cells, 
regeneration and tissue repair in different animal mod-
els. Unquestionably, to move stem cell from promising 
research into practice will require contributions from 
fundamental research, from developmental biology to 
the ‘omics’ technologies and advances in immunology.
In recent years, the potential of stem cell research 
for tissue engineering-based therapies and regenerative 
medicine clinical applications has also become popu-
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lar in Chile, focusing in particular on the use of adult 
stem cells (ASCs) considering the aforementioned 
law. Chile is an Asia-Pacific Economic Cooperation 
(APEC) and the first South American OCDE mem-
ber and as such has committed ‘to establish a harmo-
nized understanding of cell and tissue-based therapies 
and to establish training programs which impact on 
innovation performance, including R&D policies’ [46].
Since the pioneer work by Minguell and colleagues 
on ASCs in the late 1990s, mainly bone marrow and 
umbilical cord MSCs, ASCs have aroused considerable 
interest for potential therapeutic and drug discovery 
applications in Chile [47]. As a result, there are a num-
ber of new government initiatives to target the devel-
opment of new stem cell technologies and support reg-
istration of medical devices. Public funding (Innova 
Chile – CORFO and/or Fondef program – Conicyt) 
has supported initiatives such as Cells for Cells (C4C) 
S.A. or Inbiocriotec SA, biotech-based consortiums, 
launched as spin-off from Universities. The Center for 
Regenerative Medicine (Universidad del Desarrollo) 
and the ‘Center for Regenerative Therapy – Clínica 
Las Condes,’ the first laboratory of MSCs nation-
wide located in a private Clinic, are also subsided by 
Innova-CORFO funding.
So far, stem cell treatment has mainly involved 
proven ASCs, especially those related to bone mar-
row transplantation for malignant blood diseases. 
In 2007, a public cord blood bank (Banco de Vida; 
agreement signed between the Department of Obstet-
rics and Gynecology, Pontifical Catholic University of 
Chile and the Foundation Genómika; with CORFO 
cofunding) was established and the first allogeneic 
transplants were done [48]. There are also some experi-
mental studies for the treatment of dystrophic epi-
dermolysis bullosa, diabetes mellitus Type 1, lupus 
erythematosus, osteoarticular pediatric diseases and 
amyotrophic lateral sclerosis with small groups of 
patients [49,50]. Currently, according to Clinicaltri-
als.gov, there are two registered clinical trials for the 
use of MSC in patients in Chile. Most established 
groups offering stem cell therapy for now claim work-
ing under GMP international standards of quality 
to ensure the quality and safety of their products. It 
is of the uttermost importance to cluster and coor-
dinate hospitals to perform clinical trials involving 
stem/progenitor cells.
As stated by M Khoury, a former junior group leader 
at the Singapore-MIT Alliance for Research and Tech-
nology (SMART) in Singapore, now scientific direc-
tor of C4C: “The hype for these innovative strategies 
did not reach Chile only with hope but also with lot 
of confusions. Currently, there is an important mis-
information of the general public opinion regarding 
this topic. The doubtful claims and promises that have 
been diffused in the local media will surely impede the 
effort and the work of many of the academic labora-
tories in the country. However, a leap of faith resides 
in an emerging brain-gain trend of Chilean scientist 
working overseas, in long-term provided funding and a 
regulatory frame that is currently being drafted.”
To the best of our knowledge, no group in Chile is 
working with embrionic stem cells.
Stem cell research in Brazil
General vision
Over the past 15 years, stem cell biology has expanded 
significantly in Brazil. Among the factors that contrib-
uted to the interest for the field are historical reasons. 
Brazil has tradition in cell biology. One example dates 
back to 1952, when Rita Levi-Montalcini, invited by 
Carlos Chagas Filho, came to the Institute of Biophys-
ics, at the Federal University of Rio de Janeiro, to cul-
ture cells from the sensory dorsal root ganglia. This 
approach allowed the identification of the NGF that 
later awarded her the Nobel Prize [51].
Since then, the scientific community grew in Brazil 
to beyond 130,000 scientists, which, however, is still 
not enough for a country with over 200 million people. 
Around 250 researchers are affiliated to the Brazilian 
Association for cell therapy.
Stem cell initiatives in Brazil
In the 2000s, Brazilian scientists and physicians 
launched clinical trials testing autologous bone mar-
row stem cells to revert diabetes, stroke and heart con-
ditions. Brazil had achieved international recognition 
in the field [52] with at least 17 clinical trials in progress 
applying ASCs especially in cardiology, orthopedics, 
diabetes and neurology. While these endeavors sound 
like a good plan, the country lagged behind in the 
basic science [53,54].
As an attempt to revert this scenario, the Ministry 
of Health, Ministry of Education, Ministry of Science 
and Technology and the State Funding Agencies have 
sponsored more than 50 laboratories in 20 institutions 
spread across nine Brazilian states to study basic and 
translational aspects of stem cells. Since 2001, a total 
of US$50 million has been allocated specifically to 
support the stem cell field in Brazil.
Recent initiatives, led by Reinaldo Guimarães and 
Antonio Carlos Campos de Carvalho, former directors 
of the Department of Science and Technology at the 
Ministry of Health, with the support of the Funding 
Authority for Studies and Projects (FINEP) and the 
Brazilian Development Bank (BNDES), have also cre-
ated eight cell technology centers (CTCs) dedicated to 
stem cells. These CTCs have the mission of producing 
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adult and pluripotent stem cells to be used in research 
and future clinical trials [52].
Stem cell regulation & strengths, weaknesses  
& opportunities in Brazil
The number of stem cell articles published by Bra-
zilian researchers has increased more than 16-times; 
however, this expansion still holds Brazil in a reserved 
19th position in comparison to other countries [52]. 
Furthermore, despite the Biosafety Act, until 2014, 
only 10 original articles about human embryonic stem 
cells and 12 original articles about iPS cells have been 
published by authors affiliated with Brazilian institu-
tions [55]. During 2015, at least eight new original man-
uscripts have been published about human pluripotent 
stem cells, both embryonic and iPS, in the country.
The Biosafety Act permits scientists in Brazil to 
work with stem cells obtained from left over nonviable 
embryos that have been frozen for at least 3 years. Bra-
zil passed the legislation in 2005, however; a petition 
backed by Catholic Church challenged the law, claim-
ing that embryonic stem cell research fails to comply 
Brazilian’s Constitution and the moral principle that a 
human being has the right to live. In 2008, Supreme 
Court refused the appeal, giving authorization to 
embryonic stem cell research in the country.
A new initiative to boost basic studies was the creation 
of the Brazilian Bank of iPS cells, sponsored by the Min-
istry of Health, Ministry of Education and the Ministry 
of Science and Technology. The consortium of 14 Brazil-
ian laboratories will have 2 years to collect and reprogram 
cells from patients with 17 different diseases including 
Diabetes, Parkinson, Alzheimer, Amyothrophic Lat-
eral Sclerosis, Autism, Down Syndrome, QT long syn-
dromes, cystic fibrosis, etc. This biobank will produce 
stocks of iPS cells to the scientific community.
Bottlenecks for the progress of the stem cell field in 
Brazil comprise the modest record of scientific publica-
tions, rare interactions with industry and limited capa-
bilities to perform stem cell basic research, which could 
be bypassed by fostering scientific collaborations and 
also by bringing international scientists to work in the 
country. But to be successful in attracting foreign sci-
entists, the main barriers that are well known for Bra-
zilian scientists would have to be overcome: namely, 
the lack of speed and high costs associated with the 
import of research materials [56,57], together with 
the lack of guarantee of constant funding, especially 
following the recent presidential election.
Stem cell research in Argentina
General vision
Argentina has a long tradition in high-quality scientific 
research, based on the free access to public education, 
including university, and the excellent training of its 
human resources. Three Nobel Prizes in medicine and 
chemistry (Bernardo Houssay, Luis F Leloir and Cesar 
Milstein) account for this aspect, even though Milstein 
developed his work abroad.
However, the scientific productive matrix was tra-
ditionally affected by political turmoil. The budget 
dedicated to scientific research was one of the first to 
be trimmed upon an economical and/or political cri-
sis. This situation led to the emigration of well-trained 
Argentine scientists, generating massive brain drain-
age. The country suffered a last economic crisis in 
2001. Since 2003, a sustained, proactive policy in favor 
of scientific research and development has invigorated 
scientific research in our country, as in no other histori-
cal period. This political decision to support scientific 
research was embodied and exalted by the creation of 
the Ministry of Science, Technology and Productive 
Innovation (MSTPI) of Argentina in 2007 [58]. Since 
its creation, scientific infrastructure was increased 
with more than 150,000 m2 and the brain drainage 
was reverted by the return of more than 1200 scientists 
from abroad [58]. A study published by Nature in 2014, 
indicates that Argentina was the second most prolific 
country in terms of publications in the region, after 
Brazil and the impact factor of its publications grew 
over the international and regional average [44]. Argen-
tina also possesses the highest number of researcher per 
capita (3 every 1000 workers), only below the USA [44].
Importantly, a national strategic plan was generated 
as a result of several rounds of consultations among 
300 scientists, clinicians, entrepreneurs, regulators, 
public officers and other key stakeholders [59]. This 
plan defines priorities on research and development in 
the health, energy, agroindustry, environment and sus-
tainable development, social development and industry 
sectors till the year 2020.
In the health sector, one main strategic area is Regen-
erative Medicine and Tissue Bioengineering [59]. Thus, 
Regenerative Medicine is a main priority of the Argen-
tine government in terms of research and development. 
This definition initiated a number of stem cell-related 
initiatives by the MSTPI to develop this field. In par-
allel, since access to health is a constitutional right in 
Argentina, it is of fundamental importance to be able 
to provide stem cell treatments in the country that are 
approved worldwide.
Stem cell regulation in Argentina
In 2007, the Ministry of Health has passed an internal 
regulation (610-2007) defining the National Regula-
tory Authority on organ, tissue and cell transplanta-
tion (INCUCAI) as the regulatory authority on cell 
therapy. Also, INCUCAI has generated Guidelines 
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for Good Laboratory and Manufacturing Practice for 
Cellular Preparations in 2012. In addition, Argentina 
has contributed to the Spanish version of the web page 
from the ISSCR on unproven stem cell treatments. 
Still, offerings of unproven stem treatments can be 
detected. As a consequence, law to regulate all aspects 
of cell therapy is under preparation. As a weakness, 
areas such as embryonic stem cell research are not 
clearly regulated.
Stem cell initiatives in Argentina
Due to the increased support to research in general 
and stem cell-research in particular, the field has expe-
rienced a blossom. The 18 stem cell research projects 
funded in 2008 increased to 47 projects in 2012.
In 2008, as a result of a Request For Applica-
tions from MSTPI, a stem cell consortium called 
CICEMA was generated [60]. CICEMA is composed 
by 11 organizations including clinics, basic and 
translational research groups, a technology trans-
fer unit, as well as private foundations and compa-
nies. All projects require the interaction of differ-
ent groups and each composing institution provides 
matching funds to the initiative. In addition, this 
array of institutions promotes the translation of the 
consortium’s research in cardiology, neurology and 
cancer to a clinical setting.
In order to speed up the impact of reprogram-
ming technology on stem cell research, PLACEMA, a 
human iPS cell platform was financed by the MSTPI 
in 2012 [61]. PLACEMA’s objective is to provide the sci-
entific community, the clinics and the pharmaceutical 
industry with state-of-the-art reprogramming and cell 
differentiation services. The ultimate goal is to produce 
GMP-grade cells for which GMP facilities are under 
construction. The MSTPI is supportive of an interna-
tional initiative to generate a global GMP-compliant 
iPS cell bank of nondiseased donors homozygous for 
highly represented human leukocyte antigen (HLA) 
subtypes. This so-called Haplobank should enable 
future iPS cell-derived therapies compatible with a high 
percentage of the HLA repertoire of the local popu-
lation and, in a similar fashion as the bone marrow 
donors worldwide, should contribute internationally 
with requests of iPS cells with defined HLA [62].
Lino Barañao, the Minister of STPI of Argentina 
has created an Advisory Committee on Cell Thera-
pies and Regenerative Medicine in 2006, when he 
was head of the National Agency for the Promotion 
of Science and Technology. This Advisory Commit-
tee is composed of 16 members including scientists, 
lawyers, regulators, bioethicists and medical doctors 
and functions nowadays under the MSTPI [63]. Its 
mission is to advise the government and the general 
public in all areas of the stem cell field and has become 
a main advocate against stem cell tourism. Interna-
tionally, a Binational Program on Cell Therapy with 
Brazil (PROBITEC) is running since 2008 [63]. This 
program fosters the development of human resources 
by international courses and research development 
by joint research projects. Eight basic-translational 
research projects are in progress as well as a binational 
clinical trial on the use of bone marrow mononuclear 
cells in stroke patients. In addition, the PROBITEC 
coorganized the I Latin American, VIII Brazilian 
and I Argentine Congress on Stem Cell Research and 
Cell Therapy that took place at Foz de Iguazú, Brazil 
in 2014, gathering main scientists and stakeholders 
in the field from Chile, Mexico, Uruguay, Brazil, 
Argentina, USA and Europe [64]. Furthermore, a 
very successful MSTPI-ISSCR congress took place 
in Buenos Aires in 2009. Besides renowned scientists 
from the region and the world, it is noteworthy that 
the event was inaugurated by the President of Argen-
tina, Cristina Fernandez de Kirchner, as a sign of the 
public support to this research area [65].
Strengths, weaknesses & opportunities in 
Argentina
As mentioned before, governmental support is a 
main strength and driving force in stem cell research. 
Increased and improved infrastructure, augmented 
critical mass in qualified human resources, promotion 
of international cooperation and enhanced research 
budget are pillars for stem cell development in Argen-
tina. Currently, the investment in science and technol-
ogy accounts for 0.65% of the country GDP, an incre-
ment of 0.16% since 2008. However, despite proactive 
governmental policies to involve the private sector in 
R&D, only 25% of this investment comes from the 
private sector.
In terms of established stem cell treatments such as 
bone marrow transplantation for blood-derived dis-
eases, Argentina possesses the required infrastructure 
and know-how to facilitate its access to patients in 
the vast majority of the country. In addition, a pub-
lic cord blood bank, located at the Garrahan Hospi-
tal, is world-wide recognized by its excellence and it is 
certified internationally by the AABB [1]. In parallel, 
an Argentine Bone Marrow registry with over 45,000 
donors registered operates under the INCUCAI and 
in coordination with the bone marrow donors world-
wide [66]. In conclusion, Argentina has the necessary 
human and material resources to provide, at the high-
est international standards, established treatments 
using bone marrow for blood-related diseases.
As weaknesses, the country still misses human 
resources on strategic areas such as tissue bioengineer-
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Executive summary
Stem cell research in Uruguay
•	 In Uruguay medical research is scarce, as it is the national funding devoted to it. In the last years, some 
strategies like the Program for Biomedical Research (PROINBIO) and the creation of the National Agency for 
Research and Innovation are helping to foster research in this area.
•	 Due to some offers of unproven treatments, a strategic plan was developed by the Ministry of Health to 
promote regulations about standards, quality control and safety for cells and human tissue transplantation 
concurrently with the creation of the National Ethics Committee for Human Research and the Ethics 
Committee of the Medical College.
•	 The main stem cell initiatives include the creation of the National Public Umbilical Cord Blood Bank, the 
construction of a GMP Facility for Advanced Therapies with a Tissue Engineering Laboratory and a Cell 
Therapy Unit and the development of a Cell Therapy and Regenerative Medicine Training Program as national 
projects.
Stem cell research in Mexico
•	 Although Mexico has a high economical ranking, its investment in science, technology and innovation is scarce 
and should increase to at least 1% of GDP in the short term.
•	 Mexican scientists have published stem cell papers from the mid-1990s and the Mexican Society for Stem Cell 
Research was created in 2014.
•	 Both private and public umbilical cord blood banks are available and treatments for patients with 
hematological disorders have been made for more than two decades.
•	 Legislation on pluripotent stem cell derivation and oversee on the clinical application of unproven treatments 
are urgently needed.
Stem cell research in Chile
•	 Chile does not currently have a specific regulation or set of guidelines related to biomedical scientific research 
or clinical trials with human stem cells. On-going plans foresee the establishment of The Chilean Society 
for Stem Cell Research and Regenerative Medicine aiming to advocate government and relevant regulatory 
authorities on policy-making and legislation on stem cell biology and to promote the disciplines of stem cell 
research and therapies.
•	 Main initiatives include the recent creation of the Ministry of Science, Technology and Productive Innovation 
and significant investment in the last decade in both publicly funded organizations and companies that 
are becoming involved particularly in adult stem cell research and in the development of new stem cell 
technologies and support registration of medical devices.
Stem cell research in Brazil
•	 Key initiatives of Brazil include the Biosafety Act, which allows scientists to work with human embryonic stem 
cells, a national network of cell therapy and the creation of several cell technology centers to cultivate cells 
under GMP conditions.
•	 As weaknesses, Brazil has issues on importation of scientific goods, low critical mass, a modest record of 
scientific publications and rare interactions with industry.
•	 Brazil has developed capacity to run clinical trials using stem cells.
•	 Creation of a disease-oriented bank of induced pluripotent stem cells (iPS) is seen as an opportunity.
Stem cell research in Argentina
•	 This country has experienced a formidable growth in its economy and scientific investment in the last 12 years. 
This political decision to support scientific research was embodied and exalted by the creation of the Ministry 
of Science, Technology and Productive Innovation in 2007.
•	 A national strategic plan on research and innovation was created that includes Regenerative Medicine as a 
strategic area.
•	 The Ministry of Health has passed an internal regulation on cell therapy in 2007. Guidelines for Good 
Laboratory and Manufacturing Practice for Cellular Preparations are in place since 2012. Still, offerings of 
unproven stem treatments can be detected and no legislation on embryonic stem cells is available.
•	 Stem cells initiatives include a stem cell consortium, a human iPS platform, an advisory committee, a binational 
cooperation program on cell therapy with Brazil, an iPS HLA-selected Haplobank and an increase of 261% of 
stem cell research projects between 2008 and 2012.
•	 In general terms, Latin American countries have developed a renewed interest in research and development in 
the last years, in hand with economic growth.
•	 In parallel to this, stem cell research has been defined as a priority research area in many Latin American 
countries.
•	 These countries also share concerns toward unproven stem cell treatments and regulatory loopholes or 
absence of regulation.
796 Regen. Med. (2015) 10(6) future science group
Review    Palma, Pitossi, Rehen, Touriño & Velasco
ing, 3D bioprinting and translational research in gen-
eral. Most of stem cell research is located in Buenos 
Aires and its surrounding areas. In addition, only five 
clinical trials are in progress, highlighting the strength 
in basic/translation research and a deficit in moving 
forward to the clinical stage [63].
As an emerging field, stem cell research creates a 
variety of opportunities for development and coopera-
tion internally and at the international level.
Conclusions & future perspective
Latin American investigators working with stem cells 
have several problems to deal with such as few initia-
tives that frequently have limited funding and insuf-
ficient colleagues working at the bench and in the 
clinic. Defects in medical and/or regulatory oversight 
are an issue that are not distinctive of this region, since 
proper behavior of physicians offering novel treatments 
involving stem cells is mandatory worldwide [67–69]. 
On the other hand, the combination of a fast-growing 
field in a fast-growing region creates a unique oppor-
tunity for scientific and regional development, which 
must be based on open interactions among countries in 
the region and worldwide, public and private support 
and clear regulations. Besides keeping and increasing 
the excellence of the quality of scientific publications, 
initiatives, such as the iPS Haplobank, that relies on 
the regional characteristics of the HLA profile of the 
population of each country should be points of conver-
gence to integrate to the global stem cell community.
In the region, biologists, clinicians, regulators and 
bioethicists should come together to establish proper 
and stringent regulations and standards for stem cells 
therapies, being important to articulate these criteria 
for the Latin America region.
Our shared vision is that our countries should keep 
an effort in promoting innovative research of excel-
lence, establish or improve regulations to the highest 
international level, increase regional and international 
cooperation and identify country- or region-specific 
opportunities to collaborate worldwide without dimin-
ishing identity or sovereignty. The vastness and early 
development of the field provides a unique opportu-
nity to find topics or areas of collaboration where 
the strengths of each country could be value in a 
win-to-win collaborative frame.
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